EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

mTORopathies in Epilepsy and Neurodevelopmental Disorders: The Future of Therapeutics and the Role of Gene Editing

Marina Ottmann Boff iD, Fernando Antônio Costa Xavier iD, Fernando Mendonça Diz iD, Júlia Budelon Gonçalves, Laura Meireles Ferreira, Jean Zambeli, Douglas Bottega Pazzin iD, Thales Thor Ramos Previato, Helena Scartassini Erwig, João Ismael Budelon Gonçalves iD, Fernanda Thays Konat Bruzzo, Daniel Marinowic und 2 weitere

Cells · 2025

DOI: 10.3390/cells14090662 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Marina Ottmann Boff und 13 weiteren Autor:innen. Beteiligte Einrichtung: Brain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre 90610-000, RS, Brazil. Hauptthemen laut MEDLINE: Gene Editing, Neurodevelopmental Disorders, TOR Serine-Threonine Kinases, Epilepsy. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 197 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pontifical Catholic University of Rio Grande do Sul (PUCRS) - Brain Institute of Rio Grande do Sul (BraIns), CNPq, FINEP.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

mTORopathies represent a group of neurodevelopmental disorders linked to dysregulated mTOR signaling, resulting in conditions such as tuberous sclerosis complex, focal cortical dysplasia, hemimegalencephaly, and Smith–Kingsmore Syndrome. These disorders often manifest with epilepsy, cognitive impairments, and, in some cases, structural brain anomalies. The mTOR pathway, a central regulator of cell growth and metabolism, plays a crucial role in brain development, where its hyperactivation leads to abnormal neuroplasticity, tumor formation, and heightened neuronal excitability. Current treatments primarily rely on mTOR inhibitors, such as rapamycin, which reduce seizure frequency and tumor size but fail to address underlying genetic causes. Advances in gene editing, particularly via CRISPR/Cas9, offer promising avenues for precision therapies targeting the genetic mutations driving mTORopathies. New delivery systems, including viral and non-viral vectors, aim to enhance the specificity and efficacy of these therapies, potentially transforming the management of these disorders. While gene editing holds curative potential, challenges remain concerning delivery, long-term safety, and ethical considerations. Continued research into mTOR mechanisms and innovative gene therapies may pave the way for transformative, personalized treatments for patients affected by these complex neurodevelopmental conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene EditingNeurodevelopmental DisordersTOR Serine-Threonine KinasesEpilepsyHumansAnimalsGenetic TherapyCRISPR-Cas Systems

Stichwörter der Autor:innen

CRISPR/Cas9epilepsyexosomesextracellular vesiclesgene therapymTORmTORopathy

Substanzen

TOR Serine-Threonine KinasesMTOR protein, human

Autor:innen und Institutionen

  • Brain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre 90610-000, RS, Brazil.
  • School of Medicine, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre 90619-900, RS, Brazil.
  • Graduate Program in Medicine and Health Sciences, School of Medicine, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre 90619-900, RS, Brazil.
  • School of Medicine, University of the Valley of the Rio dos Sinos (UNISINOS), São Leopoldo 93022-750, RS, Brazil.
  • Graduate Program in Pediatrics and Child Health, School of Medicine, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre 90619-900, RS, Brazil.
  • Graduate Program in Biomedical Gerontology, School of Medicine, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre 90619-900, RS, Brazil.

ORCID-Profile: Marina Ottmann Boff, Fernando Antônio Costa Xavier, Fernando Mendonça Diz, Douglas Bottega Pazzin, João Ismael Budelon Gonçalves, Jaderson Costa da Costa, Gabriele Zanirati

Förderung

  • Pontifical Catholic University of Rio Grande do Sul (PUCRS) - Brain Institute of Rio Grande do Sul (BraIns)
  • CNPq
  • FINEP
  • Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS)
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brazil (CAPES)
  • Pontifical Catholic University of Rio Grande do Sul (PUCRS)
  • Brain Institute of Rio Grande do Sul (BraIns)

Zitieren

APA

Boff, M. O., Xavier, F. A. C., Diz, F. M., Gonçalves, J. B., Ferreira, L. M., Zambeli, J., Pazzin, D. B., Previato, T. T. R., Erwig, H. S., Gonçalves, J. I. B., Bruzzo, F. T. K., Marinowic, D., da Costa, J. C., & Zanirati, G. (2025). mTORopathies in Epilepsy and Neurodevelopmental Disorders: The Future of Therapeutics and the Role of Gene Editing. Cells. https://doi.org/10.3390/cells14090662

Vancouver

Boff MO, Xavier FAC, Diz FM, Gonçalves JB, Ferreira LM, Zambeli J, et al. mTORopathies in Epilepsy and Neurodevelopmental Disorders: The Future of Therapeutics and the Role of Gene Editing. Cells. 2025. doi:10.3390/cells14090662

BibTeX
@article{Boff2025,
  author = {Boff, Marina Ottmann and Xavier, Fernando Antônio Costa and Diz, Fernando Mendonça and Gonçalves, Júlia Budelon and Ferreira, Laura Meireles and Zambeli, Jean and Pazzin, Douglas Bottega and Previato, Thales Thor Ramos and Erwig, Helena Scartassini and Gonçalves, João Ismael Budelon and Bruzzo, Fernanda Thays Konat and Marinowic, Daniel and da Costa, Jaderson Costa and Zanirati, Gabriele},
  title = {mTORopathies in Epilepsy and Neurodevelopmental Disorders: The Future of Therapeutics and the Role of Gene Editing},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14090662}
}
Kostenlos starten →